id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15365 R63210 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Neonatal complications | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.82 [0.28;2.40] C excluded (control group) |
5/27 23/106 | 28 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15366 R63223 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Neonatal complications | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.98 [0.32;3.02] C | 5/27 15/80 | 20 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6685 R18606 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.67 [0.37;59.40] C excluded (control group) |
1/3 6/62 | 7 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6689 R18723 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.50 [0.08;26.86] C | 1/3 2/8 | 3 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.04 [0.37;2.96] | 23 | 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 6685, 15365